The technologies will help proteomics scientists identify an increased number of new drug and disease targets, therapeutic targets and biological markers
Agilent Technologies and Large Scale Biology have announced a worldwide licensing agreement that will allow Agilent to exclusively develop new technologies for the separation of low-abundance proteins from serum samples, such as blood.
The technologies will help proteomics scientists identify an increased number of new drug and disease targets, therapeutic targets and biological markers.
The technology will be combined with Agilent's LC/MS based systems to create complete proteomics solutions.
Products will also be made available in other formats for those proteomics scientists utilising other methods of analysis.
"This agreement builds upon the unique strengths of both of our companies and makes available the best possible solutions and tools to the life science community, and is an example of our continued commitment to developing our life sciences business," said Fran DiNuzzo, vice president and general manager of Agilent's Life Sciences and Chemical Analysis consumables and services business.
"We are delighted to have this opportunity to work with Agilent," said John Fowler, president of LSBC.
"This relationship will help commercialise more broadly a piece of the leading-edge proteomics technology developed and practiced at LSBC.
This deal underscores the creativity and innovation of our superior team of research scientists in the proteomics field."
